UK-based clinical genomics interpretation software provider Congenica has partnered with Irish SFI Research Centre FutureNeuro to develop new software for quick and accurate detection of genetic epilepsies.

The new software will use electronic health record (EHR) systems to ensure that clinicians and patients will be able to access the complete diagnostic process through their digital records.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To be based on Congenica’s clinical genomics analysis software called Sapientia, the research will be carried out at the FutureNeuro Human Genetics lab in Dublin, Ireland.

The new tool, which examines the structure, function, mapping, and editing of genomes on a molecular level, is intended to facilitate tailored treatment decisions and improve therapy options for some types of genetic epilepsy.

FutureNeuro clinical neurologist Dr Norman Delanty said: “Genomics is changing clinical medicine.

“The firms plan to provide better insights into the causes of various epilepsies and accelerate the combination of genomics and electronic health records.”

“Neurologists need to embrace it as a new powerful diagnostic tool to allow us to understand the many challenging faces of epilepsy, and lead us to individualising treatment and prognosis in the clinic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the initial stages of the partnership, the diagnostic potential of Sapientia for epilepsy will be advanced by linking the software’s knowledgebase of epilepsy data to genetic sequencing activities within FutureNeuro.

Congenica CEO Dr David Atkins said: “The types of genetic mutations that this project will focus on are thought to be at the root of as much as 40% of childhood epilepsy.”

Through the partnership, the firms plan to provide better insights into the causes of various epilepsies and accelerate the combination of genomics and electronic health records.